ATE118351T1 - Wirkung von hormonen. - Google Patents

Wirkung von hormonen.

Info

Publication number
ATE118351T1
ATE118351T1 AT89906681T AT89906681T ATE118351T1 AT E118351 T1 ATE118351 T1 AT E118351T1 AT 89906681 T AT89906681 T AT 89906681T AT 89906681 T AT89906681 T AT 89906681T AT E118351 T1 ATE118351 T1 AT E118351T1
Authority
AT
Austria
Prior art keywords
pct
inhibin
sec
host
activin
Prior art date
Application number
AT89906681T
Other languages
English (en)
Inventor
Kretser David Morritz De
David Mark Milne-Robertson
Mark Peter Hedger
Original Assignee
Biotech Australia Pty Ltd
Univ Monash
Prince Henrys Inst Med Res
St Vincents Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd, Univ Monash, Prince Henrys Inst Med Res, St Vincents Inst Med Res filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of ATE118351T1 publication Critical patent/ATE118351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Lock And Its Accessories (AREA)
AT89906681T 1988-05-31 1989-05-31 Wirkung von hormonen. ATE118351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI853488 1988-05-31
AUPJ147088 1988-11-15

Publications (1)

Publication Number Publication Date
ATE118351T1 true ATE118351T1 (de) 1995-03-15

Family

ID=25643485

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89906681T ATE118351T1 (de) 1988-05-31 1989-05-31 Wirkung von hormonen.

Country Status (5)

Country Link
US (1) US5196192A (de)
EP (1) EP0368992B1 (de)
AT (1) ATE118351T1 (de)
DE (1) DE68921150T2 (de)
WO (1) WO1989011862A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
AU7321891A (en) * 1990-02-15 1991-09-03 Cetus Corporation Inhibitor of cytokine activity and applications thereof
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
EP0661993B1 (de) * 1992-09-16 1997-05-07 Genentech, Inc. Schutz gegen leberschäden mit hgf
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
EP0833656A4 (de) * 1995-06-09 1999-02-03 Yeda Res & Dev Restrictine p/activine a enthaltende pharmazeutische zusammensetzungen und ihre verwendung als il-6 oder/und il-11 antagonisten
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
AUPO638897A0 (en) * 1997-04-23 1997-05-22 Monash University Modulation of cell growth and methods relating thereto
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
JPH11196864A (ja) 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
EP0974650A1 (de) * 1998-07-22 2000-01-26 University Of Ioannina/Medical School Inhibitoren des Endothelzellwachstums
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
AU4437485A (en) * 1984-06-08 1986-01-10 Biotechnology Australia Proprietary Limited Inhibin isolated from ovarian follicular fluid
KR940004077B1 (ko) * 1985-04-18 1994-05-11 바이오테크놀로지 오스트레일리아 프로프라이어터리 리밋티드 재조합 인히빈
AU5903986A (en) * 1985-04-18 1986-11-05 Biotechnology Australia Proprietary Limited Recombinant inhibin
AU610821B2 (en) * 1985-04-18 1991-05-30 Inhibin Pty Limited Recombinant inhibin
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
WO1988005789A1 (en) * 1987-01-29 1988-08-11 Biotechnology Australia Pty. Ltd. Isolation of single chain proteins with fsh suppressing activity from follicular fluid
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis

Also Published As

Publication number Publication date
EP0368992B1 (de) 1995-02-15
DE68921150D1 (de) 1995-03-23
EP0368992A4 (en) 1991-04-03
US5196192A (en) 1993-03-23
DE68921150T2 (de) 1995-06-14
WO1989011862A1 (en) 1989-12-14
EP0368992A1 (de) 1990-05-23

Similar Documents

Publication Publication Date Title
DE68921150D1 (de) Wirkung von hormonen.
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
BR0007719A (pt) Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
BR9608612A (pt) Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
SE9404196D0 (sv) New antithrombotic formulation
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
FI924553A0 (fi) Tiofensulfonamider anvaendbara som kolanhydrasinhibitorer
ATE189119T1 (de) Neue emulsionsformulierung
NO20000378D0 (no) Anvendelse av MHC klasse II ligander som adjuvantia for vaksinasjon og LAG-3 i kreftbehandling
AU7814498A (en) Multivalent (in ovo) avian vaccine
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
NL300187I1 (nl) Acellulair vaccin.
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
DK0686155T3 (da) Xanthinderivater som adenosin A1-receptor-antagonister
DK0471718T3 (da) Paracetamolholdigt farmaceutisk præparat
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
DE58904108D1 (de) Arzneimittel.
DK0835309T3 (da) Vaccine imod infektiøse agenser, præparat til behandling og forebyggelse af HIV infektioner
SE8402199D0 (sv) Pharmazeutisches preparat enthaltend co-dergocrine und einen calcium-antagonisten
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
DE3879837D1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties